Skip to Main Content

Paper Details

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Nat Commun
1
2023
B, BCR, BCR repertoire, EveNT, HER2, HER2-positive breast cancer, PAM50, TCR, immune-enriched tumors, lapatinib, paclitaxel, patients, stromal tumor-infiltrating lymphocyte, trastuzumab, tumor, women
Author NameAffiliation
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina
Eric P WinerYale Cancer Center, Yale School of Medicine
William F SymmansUniversity of Texas, MD Anderson Cancer Center
Ian E KropYale Cancer Center, Yale School of Medicine
Lajos PusztaiYale Cancer Center, Yale School of Medicine
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina
Christos SotiriouInstitut Jules Bordet, Hopital Universitaire de Bruxelles (H.U.B), Universite Libre de Bruxelles (ULB)
  • 1 - 8

Datasets

Release 1.2